IMMUNITYBIO INC (IBRX) Stock Price, Quote, News and Overview
NASDAQ:IBRX - Nasdaq - US45256X1037 - Common Stock - Currency: USD
IBRX Quote, Performance and Key Statistics
2.69
0 (0%)
The current stock price of IBRX is 2.69 USD. In the past month the price decreased by -1.82%. In the past year, price decreased by -63.4%.
IBRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.5 | 313.20B | ||
| AMGN | AMGEN INC | 14.02 | 149.41B | ||
| GILD | GILEAD SCIENCES INC | 23.08 | 132.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1698 | 126.59B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.88 | 64.26B | ||
| ARGX | ARGENX SE - ADR | 319.7 | 36.31B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.48B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.60B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.85B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 24.51B | ||
| NTRA | NATERA INC | N/A | 20.08B | ||
| BIIB | BIOGEN INC | 7.17 | 17.30B |
Related stock screener links
About IBRX
Company Profile
ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 680 full-time employees. The company went IPO on 2015-07-28. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.
Company Info
IMMUNITYBIO INC
3530 John Hopkins Court
San Diego CALIFORNIA 92121 US
CEO: Richard Adcock
Employees: 622
Company Website: https://immunitybio.com/
Investor Relations: https://ir.immunitybio.com/
Phone: 18446965235
IMMUNITYBIO INC / IBRX FAQ
What is the stock price of IMMUNITYBIO INC today?
The current stock price of IBRX is 2.69 USD.
What is the ticker symbol for IMMUNITYBIO INC stock?
The exchange symbol of IMMUNITYBIO INC is IBRX and it is listed on the Nasdaq exchange.
On which exchange is IBRX stock listed?
IBRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMMUNITYBIO INC stock?
11 analysts have analysed IBRX and the average price target is 11.48 USD. This implies a price increase of 326.58% is expected in the next year compared to the current price of 2.69. Check the IMMUNITYBIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMMUNITYBIO INC worth?
IMMUNITYBIO INC (IBRX) has a market capitalization of 2.37B USD. This makes IBRX a Mid Cap stock.
How many employees does IMMUNITYBIO INC have?
IMMUNITYBIO INC (IBRX) currently has 622 employees.
What are the support and resistance levels for IMMUNITYBIO INC (IBRX) stock?
IMMUNITYBIO INC (IBRX) has a support level at 2.41 and a resistance level at 2.69. Check the full technical report for a detailed analysis of IBRX support and resistance levels.
Is IMMUNITYBIO INC (IBRX) expected to grow?
The Revenue of IMMUNITYBIO INC (IBRX) is expected to grow by 595.36% in the next year. Check the estimates tab for more information on the IBRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IMMUNITYBIO INC (IBRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IBRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IBRX, evaluating the profitability, health, valuation and growth aspects
- IMMUNITYBIO INC (IBRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMMUNITYBIO INC (IBRX) Sales and EPS estimates to see what analysts future expectations are.
- IMMUNITYBIO INC (IBRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMMUNITYBIO INC (IBRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMMUNITYBIO INC (IBRX) Stock Chart to make your own analysis
- IMMUNITYBIO INC (IBRX) Latest news and press-releases to stay up to date.
Does IMMUNITYBIO INC (IBRX) stock pay dividends?
IBRX does not pay a dividend.
When does IMMUNITYBIO INC (IBRX) report earnings?
IMMUNITYBIO INC (IBRX) will report earnings on 2025-05-08, after the market close.
What is the Price/Earnings (PE) ratio of IMMUNITYBIO INC (IBRX)?
IMMUNITYBIO INC (IBRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
What is the Short Interest ratio of IMMUNITYBIO INC (IBRX) stock?
The outstanding short interest for IMMUNITYBIO INC (IBRX) is 19.34% of its float. Check the ownership tab for more information on the IBRX short interest.
IBRX Technical Analysis
IBRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IBRX. Both the profitability and financial health of IBRX have multiple concerns.
IBRX Financial Highlights
Over the last trailing twelve months IBRX reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 46.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -108% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IBRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to IBRX. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 15.56% and a revenue growth 595.36% for IBRX